D. Boral Capital initiated coverage of Pulmonx (LUNG) with a Buy rating and $17 price target The firm says Pulmonx is a commercial-stage medical technology company developing minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease. With increasing physician adoption of the company’s Zephyr Endobronchial Valve, strong reimbursement tailwinds, and international expansion opportunities, Pulmonx is well positioned for “significant growth,” the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG:
- Pulmonx management to meet virtually with Lake Street
- Pulmonx Corporation’s Earnings Call Reveals Strong Growth and Challenges
- Strong Financial Performance and Strategic Initiatives Drive Pulmonx’s Buy Rating
- Pulmonx Corporation Achieves Record Revenue Growth in 2024
- Closing Bell Movers: Carvana down 8% on earnings, Palantir extends decline
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue